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Background: For thousands of years, it remains unclear why Chinese prefer complex herbal remedy and seldom
try to purify it. One of the reasons is that they believe Chinese herbs compared to Western drugs are relatively less
toxic and better tolerated. The so called “Junn-Chenn-Zuou-SS” theory illustrates a concept of coordinated effects
from a combination of different Chinese herbs. PG27, a refined extract from a well-known Chinese antirheumatic
herb Tripterygium wilfordii Hook f (TwHf), is effective in attenuating transplantation rejection and extending survival
of cardiac xenografts.
Methods: Experiments were conducted in human primary T lymphocytes isolated from buffy coat. The activities of
the inhibitor of kappaB alpha kinase-inhibitor of kappaB alpha-nuclear factor kappaB (IKK-IκBα-NF-κB) and mitogen
activated protein kinase-activator protein-1 (MAPK-AP-1) signaling pathways were determined via electrophoretic
mobility shift assays, immunoprecipitation kinase assays, Western blots, and transfection assays.
Results: We showed that PG27 inhibited IKKα-IκBα-NF-κB and MAPK-AP-1 signaling pathways; however, IKKβ activity
was less susceptible to inhibition by PG27. In contrast, the purified component of TwHf, PG490 (triptolide), reduced
both MAPK-AP-1 and IKK-IκBα-NF-κB signaling pathways, including both IKKα and IKKβ, with similar potency. By
means of high performance liquid chromatography analysis, it was estimated that PG490 constituted 1.27 ± 0.06%
of the total PG27 content. Further analysis demonstrated that compared to PG490 alone, PG27 that contained an
equal amount of PG490 was less toxic and less immunosuppressive, suggesting the presence of cytoprotective
ingredient(s) in the non-PG490 components of PG27.
(Continued on next page)* Correspondence: laiandho@gmail.com
6Division of Allergy, Immunology and Rheumatology, Department of Internal
Medicine, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan,
Taiwan, R. O. C
Full list of author information is available at the end of the article
© 2013 Ho et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Ho et al. Journal of Translational Medicine 2013, 11:294 Page 2 of 15
http://www.translational-medicine.com/content/11/1/294(Continued from previous page)
Conclusions: In addition to demonstrating the immunomodulatory capacity of PG27 as the potential therapeutics
for arthritis and prevention of transplantation rejection, the differential regulatory effects and mechanisms by PG27
and PG490 further support in part a possibly-existing Chinese herbal theory “Junn-Chenn-Zuou-SS”.
Keywords: Tripterygium wilfordii Hook f, Nuclear factor kappaB, I-kappaBalpha kinase-beta, PG27, PG490 (Triptolide),
T CellsBackground
According to the concept of Chinese herbal therapy, the
greatest therapeutic effects come from a combination of
several ingredients; some of them are effective in treating
diseases and some of them modulate the function of these
active components through enhancing their efficacy, redu-
cing their side effects, or manipulating their delivery into
the target organs. The record about this concept called
“Junn-Chenn-Zuou-SS” is first published in Shen Nong
Ben Cao Jing, an earliest medical material dictionary com-
posed at the era of Qin and Han dynasties. The theory
“Junn-Chenn-Zuou-SS” has been generally adopted in
Chinese medicine practice where “Junn” represents the ac-
tive effective ingredient(s); “Chenn” is the adjunctive in-
gredient(s) enhancing the effectiveness of active ingredient
(s); “Zuou” is the complementary ingredient(s) reducing
the side effects of active effective ingredient(s) and “SS” is
the ingredient(s) helpful in delivering the active effective
ingredient(s) into the target organs. The “Junn-Chenn-
Zuou-SS” theory is presumably achieved by administering
different herbs (called “Danfang” for each herb) with
known functions together called a “Fufang” at a time. The
concept of “Fufang” in fact has already been applied in
medicine for a long time including the medications from
Western societies. Typical examples include the treat-
ments for rheumatoid arthritis (RA) [1] and HIV infection
[2]. In these examples, a combination of several drugs pre-
serving different inhibitory effects and mechanisms on
specific molecules or pathways may work together and
achieve synergistic effects. By doing this, the dosages of in-
dividual drugs may be greatly reduced to attenuate the po-
tential toxic effects from each drug and yet the effects are
synergistically enhanced. Nevertheless, there has been no
scientific evidence showing that “Junn-Chenn-Zuou-SS”
therapeutic theory may exist and work by different com-
ponents in a single herb.
The most commonly used Chinese medicine for auto-
immune disorders, such as RA, is Tripterygium wilfordii
Hook f (TwHf; known as Thunder God Vine), which has
potent immunosuppressive effects [3,4]. Currently, different
TwHf extracts are prescribed to treat autoimmune disor-
ders in mainland China. Aside from extensive clinical trials
conducted in oriental populations, the double blinded stud-
ies in RA patients of Western populations also confirm its
effectiveness [5,6]. In our previous work, we demonstratedthat TwHf is an effective immunomodulatory drug, which
acts by inhibiting T-cell activation and inducing T-cell
apoptosis [7,8]. Although the usefulness of each ingredient
of TwHf extracts has not been studied in detail, the major
therapeutic effects of TwHf have been suggested to be from
some of the ingredients such as PG490 (triptolide), tripdio-
lide, triptonide and triptophenolide [9-11].
Because the commonly prescribed TwHf preparations
are considered to have toxicities, this greatly reduces the
usefulness of this drug for clinical purposes. In order to
minimize drug toxicity yet reserve drug efficacy, further
purification of TwHf leads to the refined extract called
PG27 that shows promising effects in prevention of bone
marrow transplantation rejections [12]. Importantly, a
combination of both PG27 and cyclosporine results in
strong synergistic effects in extending the survival of
hamster-to-rat cardiac xenograft model [13]. In this con-
text, the TwHf purified product PG490 also preserves
strong immunosuppressive effects [14,15]. In the light of
the current therapeutic strategy for autoimmune disorders
with a combination of several disease-modifying antirheu-
matic drugs to increase efficacy and to reduce adverse
events [1], the exploration of effects and mechanisms of
Chinese antirheumatic drugs should bring more alterna-
tives for the therapy of autoimmune disorders.
The nuclear factor kappaB (NF-κB) family consists of
Rel-domain-containing proteins that are crucial for the
regulation of inflammation and immune responses [16,17].
In resting cells, these proteins are retained in the cytosol by
a group of inhibitory proteins such as inhibitor of kappaB
alpha (IκBα). After activation, IκBα is phosphorylated by
IκBα kinases (IKKs) such as IKKα and IKKβ, and under-
goes ubiquitination and subsequent proteosome-mediated
degradation [18]. This leads to the nuclear translocation of
NF-κB from the cytosol and induces the activation of a var-
iety of genes, leading to diseases such as RA [19]. Similar to
NF-κB, the activating protein-1 (AP-1) transcription factors,
which consist of Jun and Fos family proteins, extensively
participate in regulating cell proliferation, transformation
and death, and serve as good therapeutic targets for the
control of inflammation [20].
In this report, we investigated the effects and mecha-
nisms of PG27-mediated immunomodulation in primary
T cells. We observed that PG27 had differential immuno-
suppressive potency for IKKα and IKKβ, a phenomenon
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addition, PG27 that contained an equivalent amount of
PG490 was less toxic than PG490 alone. These observa-
tions explain in part a possible mechanism of “Junn-
Chenn-Zuou-SS” theory and provide evidence suggesting
that PG27 may be assessed for potential use as a disease-
modifying antirheumatic drug for autoimmune disorders
like RA.
Materials and methods
Preparation of PG27 and PG490
PG27 powder was prepared by Pharmagenesis (La Jolla,
California) and was kindly provided by PhytoHealth, Inc,
Taipei, Taiwan. PG490 was purchased from Sigma-Aldrich
Chemical Company (St. Louis, MO). Both drugs were dis-
solved in DMSO to generate 100 mg/mL (PG27) or
100 ng/mL (PG490) stock solutions. For experiments, the
required concentrations of each drug were made by dilu-
tion of the concentrated stock solution with culture
medium, which contained RPMI 1640 medium supple-
mented with 10% fetal bovine serum, 2 mM glutamine,
and 1,000 U/mL penicillin-streptomycin (Gibco-BRL,
Gaithersberg, MD).
Preparation of peripheral blood T cells
The use of buffy coat purchased from the blood bank
(Taipei, Taiwan) was approved by the Institutional Re-
view Board, Tri-Service General Hospital, through a fast
review tract. Human peripheral blood T cells were puri-
fied from whole blood via negative selection, according
to our previous report [8]. Briefly, buffy coat was mixed
with Ficoll-Hypaque, and the layer of mononuclear cells
was collected after centrifugation. After lysis of red
blood cells, the peripheral blood mononuclear cells
were incubated with antibodies (Abs), including L243
(anti-DR; American Type Culture Collection [ATCC],
Rockville, MD), OKM1 (anti-CD11b; ATCC), and LM2
(anti-Mac1; ATCC) for 30 min at 4°C. The cells were
washed with medium containing 10% fetal bovine serum
and incubated with magnetic beads conjugated to goat
anti-mouse IgG (R & D, Minneapolis, MN). The antibody-
stained cells were then removed with a magnet. Following
a repeat of the above procedures, T cells were obtained
with a purity of more than 98%, as determined by the
percentage of CD3+ cells in flow cytometry (Beckton
Dickinson, Mountain View, CA).
Cell stimulation, cytokine determination, and cell
survival measurement
To activate T cells, the following stimuli were used: phor-
bol 12-myristate 13-acetate (PMA; Sigma) at 10 ng/mL,
ionomycin (Sigma) at 1 μM, immobilized monoclonal
antibody (mAb) anti-CD3 (OKT3; ATCC) at 10 μg/mL,
soluble anti-CD28 mAb (Beckton Dickinson) at 1 μg/mL,and TNF-α at 10 ng/mL. The cells were incubated with
the various stimuli, and the cell pellets or supernatants
were collected for analysis. The determination of cytokine
concentrations was performed via ELISA as described pre-
viously [21]. IC50 was the concentration of drug (PG27 or
PG490) that inhibited half the cytokine production from
different stimuli-activated T cells and was calculated by
linear regression using Microsoft Excel. Cell viability was
measured by either the trypan blue exclusion assay or
the MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetra-
zolium bromide) colorimetric assay, as described in our
previous report [8]. Similarly, the 50% lethal concentra-
tions (LC50) of PG27 and PG490 were calculated.
Preparation of cytoplasmic and nuclear extracts
Cytoplasmic and nuclear extracts were prepared accord-
ing to our published work [21]. Briefly, treated cells were
incubated at 4°C in 50 μL of buffer A (10 mM HEPES,
pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 1 mM DTT, 1 mM
PMSF, 3.3 μg/mL aprotinin) for 15 min, with occasional
gentle vortexing. The swollen cells were centrifuged at
15,000 rpm for 3 min. After removal of the supernatants
(cytoplasmic extracts), the pelleted nuclei were washed
with 50 μL of buffer A, and subsequently, the cell pellets
were resuspended in 30 μL of buffer C (20 mM HEPES,
pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
25% glycerol, 1 mM DTT, 0.5 mM PMSF, 3.3 μg/mL
aprotinin) and incubated at 4°C for 30 min, with occa-
sional vigorous vortexing. The mixtures were then cen-
trifuged at 15,000 rpm for 20 min, and the supernatants
were used as nuclear extracts.
Electrophoretic mobility shift assays (EMSAs)
EMSAs were performed as detailed in our previous report
[21]. Oligonucleotides containing the NF-κB-binding site
(5′-AGT TGA GGG GAC TTT CCC AGG C-3′), the
AP-1-binding site (5′-CGC TTG ATG AGT CAG CCG
GAA-3′), and the Oct-1-binding site (5′-TGT CGA ATG
CAA ATC ACT AGA A-3′) were purchased and used as
DNA probes (Promega, Madison, WI). The DNA probes
were radio-labeled with [γ-32P]ATP using T4 kinase, ac-
cording to the manufacturer’s instructions (Promega). For
the binding reactions, the radio-labeled probes were incu-
bated with 5 μg of nuclear extracts. The binding buffer
contained 10 mM Tris–HCl, pH 7.5, 50 mM NaCl,
0.5 mM EDTA, 1 mM DTT, 1 mM MgCl2, 4% glycerol,
and 2 μg poly(dI-dC). The reaction mixtures were incu-
bated at room temperature for 20 min prior to the binding
reaction. For supershift assays, different mAbs were prein-
cubated with nuclear extracts for 30 min before the
addition of the radiolabeled probes. The final reaction
mixtures were analyzed in 6% non-denaturing polyacryl-
amide gels with 0.25× Tris-borate/EDTA as an electro-
phoresis buffer.
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ECL Western blotting (Amersham, Arlington Heights, IL)
was performed as described previously [8]. Briefly, equal
amounts of whole cell lysates and cytoplasmic or nuclear
extracts were analyzed by 10% SDS-PAGE and transferred
to a nitrocellulose filter. For immunoblotting, the nitrocel-
lulose filter was incubated with Tris-buffered saline con-
taining 5% nonfat milk (milk buffer) for 2 h, and then
blotted with antisera against IκBα, IKKα, IKKβ (Santa
Cruz Biotechnology), or β-actin overnight at 4°C. After
washing twice with milk buffer, the filter was incubated
with donkey anti-mouse IgG conjugated to horseradish
peroxidase at a concentration of 1:5,000 for 30 min. The
filter was then incubated with the substrate and exposed
to X-ray film.
Immunoprecipitation kinase assay
The immunoprecipitation kinase assay was described in
detail in our previous report [21]. The GST-IκBα fusion
protein was used as a substrate for IKKα and IKKβ. The
JNK substrate, a GST-c-Jun fusion protein, was a kind gift
from Dr. S.-F. Yang (Academia Sinica, Taiwan). Myelin
basic protein (MBP), which was used as a substrate for
both ERK and p38, was purchased from Sigma. The Abs
used for the kinase assays were purchased from Cell Sig-
naling (Beverly, MA; for anti-JNK and anti-p38 polyclonal
Abs) and Santa Cruz Biotechnology (for anti-ERK, anti-
IKKα and anti-IKKβ polyclonal Abs). To perform the im-
munoprecipitation kinase assay, 50–100 μg of whole cell
extract was incubated with 5 μL of specific Abs in an incu-
bation buffer (25 mM HEPES, pH 7.7, 300 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton-X-100,
20 mM β-glycerophosphate, 0.1 mM Na3VO4, 2 μM leu-
peptin, 400 μM PMSF) overnight. The mixture was then
immunoprecipitated by the addition of protein A beads
and rotated at 4°C for 2 h. After extensive washing, (twice
with a HEPES washing buffer [20 mM HEPES, pH 7.7,
50 mM NaCl, 2.5 mM MgCl2, 0.1 mM EDTA, 0.05% Tri-
ton X-100]; twice with an LiCl washing buffer [500 mM
LiCl, 100 mM Tris, pH 7.6, 0.1% Triton X-100, 1 mM
DTT]; and twice with a kinase buffer [20 mM MOPS,
pH 7.2, 2 mM EDTA, 10 mM MgCl2, 0.1% Triton X-100
and 1 mM DTT], the beads were resuspended in 40 μL of
kinase buffer, along with cold ATP (30 μM) and 10 μCi of
[γ-32P]ATP. The mixture was incubated at 30°C with occa-
sional gentle mixing for 30 min. The reaction was then
terminated by resuspending the samples in a 1% SDS solu-
bilizing buffer and boiling for 5 min. The samples were
then analyzed by SDS-PAGE.
Transfection assay in purified human peripheral
blood T cells
The transfection assay was performed by electroporation
with an Amaxa Nucleofector apparatus, according to themanufacturer’s instructions (Amaxa, Cologne, Germany).
In brief, primary T cells were mixed with 5 μg of the re-
porter plasmid pNF-κB-luciferase (Luc) or pAP-1-Luc
(Stratagene, La Jolla, CA) in 100 μL of the provided elec-
troporation buffer. After electroporation, the cells were
transferred to 2 mL of pre-warmed RPMI medium. After
transfection for 48 h, the cells were aliquoted equally for
testing the individual conditions described in the figure
legends. For treatment, the drugs were added 2 h before
the addition of stimuli. After stimulation with TNF-α for
18 h, the cell pellets were collected, total cell lysates were
prepared, and the luciferase activity, after normalization to
the total protein amounts, was determined according to
the manufacturer’s instructions (Promega).
Analysis of the PG490 content in PG27 by HPLC
Both PG490 (1.6 mg) and PG27 (2.4 mg) were dissolved
in DMSO (1.0 mL) to generate stock solutions. PG490
was spiked into the mobile phase to create a series of
standards consisting of 0.0125, 0.025, 0.05, 0.1, 0.2, 0.4,
0.8, and 1.6 mg/mL concentrations. High Performance
Liquid Chromatography (HPLC) was performed on an
Agilent Model 1100 Quat pump system equipped with
an Agilent 1100 VWD Detector and an Agilent 1100
ALS auto-injector. The detector was set to 218 nm. A
reversed phase column (Cosmosil 5C18-AR-II, 25 cm ×
4.6 mm I.D.) was applied. The mobile phase was 45%
MeOH/55% H2O eluted at a flow rate of 0.8 mL/min.
The injection volume was 20 μL for each sample.
Statistics
The results were expressed as means ± standard devia-
tions. One-way ANOVA analysis was used to evaluate the
differences, which were considered to be statistically sig-
nificant at a P value of <0.05.
Results
PG27 inhibited IL-2 production from activated T cells
To determine whether PG27 exhibited immunosuppressive
effects that were as potent as the crude TwHf extract, puri-
fied T cells were activated with various stimuli in the pres-
ence or absence of PG27, and IL-2 concentrations were
determined by ELISA (Figure 1). PG27 inhibited IL-2 pro-
duction induced by PMA+ ionomycin (Figure 1A) or CD3/
CD28 (Figure 1B) in a concentration-dependent manner.
There was no detectable cytotoxicity, in the presence or ab-
sence of stimulus, resulting from the tested concentrations
of PG27 (Figure 1C and data not shown).
PG27 inhibited NF-κB and AP-1 activation induced by
various stimuli
We next examined the potential effects of PG27 on the
activation of NF-κB and AP-1. After the treatment with
different stimuli in the presence or absence of various
Figure 1 PG27 inhibited IL-2 production from activated T cells in a concentration-dependent manner. Human peripheral blood T cells at
a concentration of 1 × 106/mL were pretreated with various concentrations of PG27 for 2 h and then stimulated with PMA + ionomycin
(shown as P + I) (A) or CD3/CD28 (B) for 24 h. The supernatants were collected for the determination of IL-2 concentrations. In parallel, cell
survival in the various conditions was determined by trypan blue exclusion assays (C). The results shown are from independent experiments.
Each experiment was performed in triplicate using T cells from at least 3 different donors.
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extracts were prepared and analyzed by EMSA. As shown
in Figure 2, PG27 suppressed PMA + ionomycin-induced
(Figure 2A) and CD3/CD28-induced (Figure 2B) NF-κB
and AP-1 DNA-binding activities. Considering the import-
ant role of TNF-α in inflammatory response, we also ex-
amined the effects of PG27 on TNF-α-stimulated T cells.
Consistent with the experimental results for the previous
stimuli, PG27 efficiently reduced the TNF-α-induced NF-
κB and AP-1 DNA-binding activities (Figure 2C). In con-
trast, PG27 did not affect the DNA-binding activity of thenegative control Oct-1 (Figure 2C). Furthermore, the
highest concentration of the solvent DMSO used to dis-
solve PG27 did not show any inhibitory effect on NF-κB
or AP-1 DNA-binding activity (data not shown). Using
EMSA supershift analysis, performed in the presence of
anti-p65 or anti-p50 mAbs, we further demonstrated that
the transcription factors induced by TNF-α and PMA +
ionomycin that bound the radiolabeled κB oligonucleotide
probes consisted of at least p65 and p50 (Figure 2D).
These results are consistent with the observations demon-
strated in our previous report examining nuclear extracts
Figure 2 PG27 inhibited NF-κB and AP-1 activation induced by various stimuli. Human peripheral blood T cells at a concentration of 2 ×
106/mL were pretreated with various concentrations of PG27 for 2 h and then stimulated with PMA + ionomycin for 2 h (A), CD3/CD28 for 6 h
(B) or TNF-α for 6 h (C). The nuclear extracts were prepared and analyzed for both NF-κB and AP-1 DNA-binding activity by EMSA. As a control,
the DNA-binding activity of Oct-1 was measured (C). In (D), before adding the radiolabeled oligonucleotides to the reaction mixture, the nuclear
extracts were preincubated with 5 μl of the indicated mAb for 30 min. The asterisk indicates the supershifted bands. In (E), T cells at a concentration
of 1 × 106/mL were mixed with pNF-κB-Luc or pAP-1-Luc reporter plasmids and transfection reagents. The transfection was performed using an Amaxa
Nucleofector according to the manufacturer’s instructions. After transfection for 48 h, the cells were aliquoted equally for the individual conditions and
pretreated with various concentrations of PG27 for 2 h. After stimulation with TNF-α for another 18 h, cells were collected and total cell lysates were
analyzed for luciferase activity. Cell survival was determined by trypan blue exclusion assays. Representative data of at least 3 independent experiments
are shown.
Ho et al. Journal of Translational Medicine 2013, 11:294 Page 6 of 15
http://www.translational-medicine.com/content/11/1/294from CD3/CD28-stimulated T cells [21]. To assess
whether PG27 inhibited the transcription of genes con-
taining binding sites for NF-κB and AP-1, we transiently
transfected NF-κB- or AP-1-luciferase reporter con-
structs into purified human peripheral blood T cells.
Forty-eight hours after transfection, T cells were ali-
quoted equally for the treatment with various concen-
trations of PG27 and then stimulated with TNF-α as
indicated (Figure 2E). The total cell lysates were pre-
pared and the luciferase activities were determined. The
data showed that PG27 effectively suppressed the tran-
scriptional activities of both NF-κB and AP-1 induced
by TNF-α (Figure 2E). Side-by-side examinations of cellviability revealed no significant cytotoxicity of PG27 in
all conditions tested (Figure 2E).
Effects of PG27 on IκBα degradation and IKK activity
The upstream signaling molecules that control the activa-
tion of NF-κB were examined. T cells were treated with
TNF-α for 15, 30, or 60 min in the presence or absence of
PG27, and then cytoplasmic extracts were prepared to
determine IκBα levels by Western blotting. As shown in
Figure 3A, the cytosolic levels of IκBα decreased after
TNF-α stimulation for 15 min; however, the pre-treatment
with PG27 maintained IκBα levels close to the basal level.
When nuclear extracts were examined for NF-κB DNA-
Figure 3 PG27 prevented IκBα degradation and reduced the activity of IKKα but not IKKβ. In (A), T cells were pretreated with PG27
(200 ng/mL) for 2 h or left untreated, and then stimulated with TNF-α for various lengths of time as indicated. After washing, cell pellets were
collected and cytoplasmic and nuclear extracts were prepared and analyzed for the protein levels of IκBα by Western blotting (upper panel)
and NF-κB DNA-binding activity by EMSA (lower panel), respectively. In (B), T cells were pretreated with PG27 for 2 h and then stimulated with
TNF-α for 10 min. After washing, cell pellets were collected and total cell lysates were prepared and analyzed for the kinase activity of IKKα
(upper panel) or IKKβ (middle panel) by immunoprecipitation kinase assays. The total cell lysates were also analyzed for IKKα protein levels by
Western blotting (lower panel). In (C), after pretreatment with PG27, T cells were stimulated with PMA + ionomycin for 15 min, and the cell lysates were
collected for measurement of IKKα and IKKβ activity. The densitometric intensities of the individual bands are shown. The analysis of PG27-mediated
suppression of TNF-α-stimulated IKKα and IKKβ was performed in T cells from at least 3 different donors (D). *, P value of <0.05.
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were observed (Figure 3A). Considering that the regula-
tion of IκBα protein levels depends on the activity of
IKKs, which phosphorylate IκBα leading to its ubiqui-
tination and degradation, we next wanted to deter-
mine whether PG27 could suppress IKK activity. To
this end, immunoprecipitation kinase assays were per-
formed with GST-IκBα as a substrate for both IKKα
and IKKβ. As shown in Figure 3B, PG27 at a wide
range of concentrations suppressed TNF-α-induced
IKKα activity. In contrast, TNF-α-induced IKKβ activity
was unexpectedly resistant to PG27 treatment; suppres-
sion was observed only mildly under the highest con-
centration of PG27 (Figure 3B). The differentialsuppression of IKKα and IKKβ activity by PG27 was not
due to unequal loading of total protein, because the
basal IKKα and β–actin levels appeared to be very simi-
lar for each sample (Figure 3B). To determine whether the
differential suppression of IKKα and IKKβ by PG27 was
specifically limited to TNF-α-induced signaling, additional
immunoprecipitation kinase assays were performed using
the PMA + ionomycin stimulus to treat cells. In agreement
with the results for TNF-α stimulation, PG27 also showed
preferential suppression of PMA + ionomycin-induced
IKKα activity (Figure 3C). The PG27-mediated differential
suppression of TNF-α-induced IKKα and IKKβ activities
was statistically analyzed and the results suggested that
PG27, at concentrations from 25 to 200 ng/mL, effectively
Figure 4 PG490 inhibited both NF-κB and AP-1 DNA-binding and transcriptional activity. T cells were pretreated with various
concentrations of PG490 (A) for 2 h and then stimulated with TNF-α (B) or CD3/CD28 (C) for 6 h. The nuclear extracts were analyzed for both
NF-κB and AP-1 DNA-binding activity by EMSA. In (D), T cells were pretreated with PG490 for 2 h or left untreated, and then stimulated with
TNF-α for various lengths of time as indicated. After washing, cell pellets were collected and cytoplasmic extracts were analyzed for the protein
levels of IκBα and β-actin by Western blotting. In (E), T cells were mixed together with pNF-κB-Luc or pAP-1-Luc reporter plasmids and the
transfection procedures were performed as described for Figure 2. After electroporation for 48 h, the cells were aliquoted equally and pretreated
with various concentrations of PG490 for 2 h. After stimulation with TNF-α for another 18 h, cells were collected and analyzed for luciferase
activity. Representative data of at least 3 independent experiments are shown.
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pression of IKKβ activity was observed only mildly under
the highest PG27 concentration (Figure 3D).
PG490 inhibited NF-κB and AP-1 activation
The unexpected differential effects of PG27 on IKK ac-
tivity led us to investigate the effects of the purified
TwHf component, PG490 (Figure 4A). T cells were
treated with various concentrations of PG490 and then
stimulated with TNF-α. Nuclear extracts were then pre-
pared and the DNA-binding activities of NF-κB and
AP-1 was analyzed by EMSA. As shown in Figure 4B,PG490 reduced the TNF-α-induced DNA-binding activ-
ities of both NF-κB and AP-1. Similar suppressive ef-
fects of PG490 were observed when the stimulus TNF-α
was replaced by CD3/CD28 (Figure 4C). We also
wanted to determine whether PG490 was able to regu-
late the expression of IκBα, which controls NF-κB
activation. Western blots indicated that PG490 effect-
ively inhibited the degradation of IκBα induced by TNF-
α (Figure 4D). Consistent with these data, transfection
assays demonstrated the suppressive potency of PG490
on the transcriptional activity of NF-κB and AP-1
(Figure 4E) induced by TNF-α.
Figure 5 PG490 inhibited both IKKα and IKKβ kinase activity. T cells were pretreated with various concentrations of PG490 for 2 h and then
stimulated with TNF-α for 10 min (A), PMA + ionomycin for 15 min (B) or CD3/CD28 for 30 min (C). Cell pellets were collected and total cell
lysates were prepared and analyzed for the kinase activity of IKKα and IKKβ by immunoprecipitation kinase assays. The total IKKα and/or total IKKβ
levels were determined by Western blotting. The analysis of PG490-mediated suppression of IKKα and IKKβ activities induced by TNF-α stimulation
was performed on pooled data from T cells from 3 different donors (D). *, P value of <0.05.
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To determine whether PG490 was similar to PG27 in
its inhibitory effects on TNF-α-induced IKKα and
IKKβ, immunoprecipitation kinase assays were per-
formed. Surprisingly, unlike PG27, PG490 reduced the
kinase activities of both IKKα and IKKβ to a similar
extent (Figure 5A). To investigate whether the effects
of PG490 were observed only in T cells stimulated by
TNF-α, different T cell stimuli were also examined.
Consistent with the observations in TNF-α-stimulated
cells, the kinase activities of both IKKα and IKKβ in-
duced by PMA + ionomycin (Figure 5B) or CD3/CD28
(Figure 5C) was comparably inhibited by PG490 in a
concentration-dependent manner. These results indi-
cated that the suppression of both IKKα and IKKβ by
PG490 was generally observed in human peripheral
blood T cells activated by different stimuli. For
consistency, the PG490-mediated suppression of IKKαand IKKβ activities induced by TNF-α stimulation in T
cells from 3 different donor blood was quantitatively
measured (Figure 5D).PG27 and PG490 downregulated MAPK activity
Although both PG27 and PG490 could successfully in-
hibit activation of NF-κB, they preserved differential
suppressive activity against NF-κB upstream signaling
molecules IKKα and IKKβ. Given that PG27 and PG490
could also effectively inhibit AP-1 activity, we deter-
mined whether they might have different suppressive
potency on AP-1 upstream signaling kinases. Interest-
ingly, as comparisons, the results showed that both
PG27 and PG490 could effectively suppress MAP
kinases, including JNK, p38 and ERK activities
induced by various stimuli, albeit to different degrees
(Figure 6A,B,C and D).
Figure 6 PG27 and PG490 down regulated MAPK activity. T cells at a concentration of 5 × 106/mL were pretreated with various
concentrations of PG27 (A and B) or PG490 (C and D) for 2 h and then stimulated with PMA + ionomycin for 30 min (A), TNF-α for 10 min
(B and C) or CD3/CD28 for 30 min (D). Cell pellets were collected and total cell lysates were immunoprecipitated with anti-JNK, anti-p38 or
anti-ERK antibodies. After sequential washes, the substrates (GST-c-Jun for JNK and MBP for both p38 and ERK) and [γ-32P]ATP were added
individually. After the kinase reaction, the mixture was analyzed by SDS-PAGE. Representative data of at least 3 independent experiments
are shown.
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on IL-2 production and cytotoxicity in activated T cells
Since IKKβ activity appeared to have differential suscepti-
bility to inhibition by PG27 and PG490, we took further
steps to determine whether PG490 was a component of
PG27, and if so, how much of PG27 content was consti-
tuted by PG490. We applied HPLC to examine the con-
tents of PG27 and to determine the percentage of PG490
in PG27. As shown in Figure 7, PG490 was estimated to
constitute 1.27 ± 0.06% of PG27, indicating that the high-
est concentration of PG27 used in this study (200 ng/mL)
contained approximately 2.5 ng/mL of PG490. This quan-
tity of PG490 was likely responsible in part for the
PG27-mediated inhibitory effects on the IKK-NF-κB
and MAPK-AP-1 signaling pathways. We subsequently
examined whether the presence of other non-PG490
components in PG27 may affect the immunosuppres-
sive potency and cytotoxic effects of PG490. T cells werepretreated in parallel with serial dilutions of PG490 or
PG27 that contained an equivalent amount of PG490,
and then stimulated with PMA + ionomycin. The con-
centrations of IL-2 in the culture supernatants were
measured. The results revealed that the 50% inhibitory
concentrations (IC50) for PG27 and PG490 on PMA +
ionomycin-induced IL-2 production were 39.18 ng/mL
and 0.19 ng/mL, respectively (Figure 8A). The IC50 con-
centrations for PG27 and PG490 on CD3/CD28-
induced IL-2 production were 39.67 ng/mL and 0.23
ng/mL, respectively (Additional file 1: Figure S1). These
data suggest that the low level of IKKβ-suppressive ac-
tivity in PG27 did result in a partial reduction of its
immunosuppressive potency, since PG490, which was
shown to suppress both IKKα and IKKβ, had a greater
inhibitory effect on IL-2 production. We then
determined whether the cytotoxic effects of PG490
might be augmented or alleviated by other non-PG490
Figure 7 HPLC analysis of the quantity of PG490 in PG27. The chromatogram of PG27 with PG490 is presented, showing the retention time
of 13.4 min. PG490 calibration graphs were constructed in the range of 12.5 μg/mL to 1.6 mg/mL. The regression equations of these curves and
their correlation coefficients were calculated to be y = 46682x + 82.221 (r2 = 1, top-right corner). The peak area ratios show a linear relationship
with the concentration of PG490. When the sample solution was analyzed by HPLC, the PG490 peak was confirmed by comparison to the
retention time standards. The PG490 content in PG27 was determined to be 1.27 ± 0.06%.
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with DMSO (the solvent), PG490 or PG27 that con-
tained an equivalent amount of PG490, and then stimu-
lated with PMA + ionomycin, CD3/CD28 or TNF-α.
The cell survival rate was determined by MTT colori-
metric assays. As shown in Figure 8B, the 50% lethal
concentration (LC50) of PG27 was higher than that of
PG490 alone, indicating that the non-PG490 compo-
nents of PG27 might have provided partial protection
against PG490-induced cytotoxicity. The LC50 concen-
trations for PG27 and PG490 in PMA + ionomycin-
stimulated T cells were 689.83 ng/mL and 4.49 ng/mL,
respectively; in CD3/CD28-stimulated T cells, they were
943.8 ng/mL and 4.91 ng/mL, respectively; and in TNF-
α-stimulated T cells, they were 1913.1 ng/mL and 13.9
ng/mL, respectively (Figure 8B). The higher LC50 con-
centrations in TNF-α-stimulated T cells might be due to
the potential cytotoxic effects of TNF-α, which did not
occur with PMA + ionomycin and CD3/CD28-stimu-
lated T cells.
Discussion
PG27 attracts the attention of scientists since one decade
ago with its promising immunomodulatory effects in indu-
cing antigen-specific tolerance in bone marrow trans-
planted mice [12] and the extending survival of cardiac
xenograft models [13]. The following work was postponed
because of consideration of the priority of clinical trialsby the pharmaceutical company. In considering the poten-
tial applications of PG27 for autoimmune disorders, in
the present study, we conducted molecular experiments
to examine the mechanisms of PG27-mediated immuno-
modulation in human peripheral blood T cells. PG27, at
therapeutic concentrations, not only suppressed various
stimuli-induced transcription factor DNA-binding activities
but also suppressed the transcriptional activities of both
NF-κB and AP-1 (Figure 2). To our surprise, PG27 differen-
tially regulated IKKα and IKKβ kinase activities induced by
various stimuli. In contrast, the purified TwHf component
PG490 inhibited both IKKα and IKKβ activities with similar
potency. HPLC analysis determined that PG490 constituted
1.27 ± 0.06% of PG27 content (Figure 7). Compared to
PG490 alone, PG27 that contained an equal amount of
PG490 was not only less potent in immunosuppressive ac-
tivity but also less cytotoxic in activated T cells (Figure 8).
Based upon the “Junn-Chenn-Zuou-SS” theory, the evi-
dence for PG490 working as “Junn”, the main active ingre-
dient, can be supported by its apoptosis-inducing effects
and potent immunosuppressive effects demonstrated in a
variety of tissue cells stimulated by different stimuli as well
as in animal models of autoimmune disorders [11,14,22,23].
In addition to PG490, there are many uncharacterized com-
ponents in PG27 and compared to PG490 alone, PG27 was
less toxic. It seems probable that the IKKβ-suppressive ef-
fect of PG490 was masked or neutralized by other non-
PG490 components in PG27, resulting in the reduction of
Figure 8 Side-by-side comparisons of PG27 and PG490 for immunosuppressive potency and drug cytotoxicity. T cells from a single
donor were pretreated in parallel with DMSO (Ctl) or various concentrations (in serial dilutions) of PG490 or PG27 that contained an equal
amount of PG490, and then stimulated with PMA + ionomycin (A) or 3 different stimuli (PMA + ionomycin, CD3/CD28 and TNF-α) as indicated
(B) for 24 h. In (A), the concentrations of PG27 and PG490 at 1× (the highest concentration) were 200 ng/mL and 2.56 ng/mL, respectively. In (B),
the concentrations of PG27 and PG490 at 1× (the highest concentration) were 6400 ng/mL and 81.28 ng/mL, respectively. The supernatants were
collected for the measurement of IL-2 (A) and the cells were collected for the measurement of cytotoxicity by MTT colorimetric assays (B).
The results are representative of T cells from at least 3 different donors.
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cordingly, some of these non-PG490 components may
function as “Zuou”. Because there have been no reports
simultaneously examining the combinatorial effects of two
or more than two different components of TwHf, the com-
ponents in PG27 that work as “Zuou” are currently unclear.
Further purification and examination of PG27 components
can help solve the question.
Because NF-κB transcription factors can up-regulate
many genes involved in inflammatory responses, targeting
NF-κB signaling events has been one of the major thera-
peutic goals in preventing graft rejections and in controlling
autoimmune diseases [24,25]. The commonly prescribed
disease modifying antirheumatic drugs also preserve inhibi-
tory effects against NF-κB activation [26,27]. Regarding the
significance of NF-κB in transplantation immunology, theinhibition of NF-κB by IκBα gene transfer is shown to im-
prove oxygenation of the transplanted lung [28]. Transfec-
tion with NF-κB decoy into the donor lung effectively
reduces lung injury during acute allograft rejections [29].
Like NF-κB, MAPK-AP-1 signaling pathway is also a critical
and excellent target to block in developing therapy for
inflammation-related disorders [30,31]. The inhibition of
IKKα-IκBα-NF-κB and MAPK-AP-1 signaling pathways by
PG27 and PG490 should lead them to potential candidates
of promising immunomodulatory drugs for the therapy of
autoimmune disorders and for the prevention of graft
rejections.
Three major classes of stimuli, including PMA + iono-
mycin, the CD28 costimulatory molecule, and TNF-α,
were used to activate T cells for the investigation of the im-
munomodulatory effects of PG27 and PG490 in human
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seem to affect the experimental outcomes, as the results
were consistent and reproducible regardless of the stimuli
being evaluated. PMA + ionomycin mimics a T cell
receptor-mediated stimulus that bypasses the requirement
for an antigen- or lectin-induced signal [32]. The pro-
inflammatory cytokine, TNF-α, is considered to be an im-
portant molecule for the regulation of upstream cytokine
cascades in inflammatory responses. The blockade of TNF-
α-mediated events has been found to have significant
therapeutic effects on active RA and seronegative spondy-
loarthropathies [33]. Given the significance of CD28 signal-
ing in T cell activation, blockade of the CD28 signaling
pathway is another promising therapeutic strategy for RA,
even for those who are refractory to anti-TNF therapy [34].
Considering the critical roles of T cells in autoimmune dis-
orders, we examined these crucial stimuli-activated T cells
and demonstrated the broad-spectrum immunosuppressive
capacities of both PG27 and PG490.
The differential inhibitory potency of PG27 against
IKKα and IKKβ is interesting. Studies of many different
compounds against IKK activity have indicated that for
arthritis therapeutics, the suppression of either IKKα or
IKKβ may be sufficient to block NF-κB activation [35].
The concentrations of IC50 for PG490 and PG27 with
equivalent content of PG490 on PMA + ionomycin-in-
duced and CD3/CD28-induced IL-2 production indicate
that PG490 preserved more potent immunosuppressive
activity than PG27. It suggests that the counteraction of
PG490-mediated IKKβ suppression by other components
resulted in reduction of immunosuppressive potency of
PG27. Nevertheless, the selective suppression of IKKα
but not IKKβ by PG27 may potentially lead to some ben-
efits therapeutically. For example, in knockout studies,
the targeted deletion of IKKβ results in early embryonic
lethality due to extensive apoptosis of fetal hepatocytes
[36,37]. In contrast, the deficiency of IKKα which results
in abnormal development of skin and skeleton is rela-
tively less fatal [38]. In addition, IKKβ plays a requisite
role in B cell activation and maintenance [39]. Further-
more, the preservation of intact IKKβ-NF-κB signaling
pathway is important for protecting T cells from TNF-α-
induced apoptosis [38]. According to Egan et al. [40],
in an in vivo system, the preservation of IKKβ-
dependent NF-κB activation pathway is crucial for pro-
tection against radiation-induced apoptosis in intestinal
epithelium. It is therefore possible that given an
already suppressed IKKα-NF-κB signaling pathway, the
preservation of IKKβ-NF-κB signaling pathway may
help to reduce the potential side effects of PG27 in T
cells and in other tissue cells. This suggestion was
supported by a much reduced cytotoxic effect, as com-
pared to PG490 alone, in PG27 containing equivalent
amount of PG490 content.Conclusions
In this study, we observed that PG27 and PG490 had dif-
ferential suppressive effects on IKKα and IKKβ activities
induced by a variety of stimuli in T cells. The results also
suggest that compared to PG490 alone, PG27 that con-
tained an equivalent amount of PG490 caused less cell
death. In light of the current therapeutic strategy for auto-
immune disorders, which involves the combination of sev-
eral disease-modifying antirheumatic drugs to increase
efficacy and reduce adverse events [1], the exploration of
the effects and mechanisms of Chinese antirheumatic
drugs such as PG27 should provide additional alternatives
for the therapy of autoimmune disorders like RA.
There are several limitations in this report. Firstly, it re-
mains unclear the components responsible for counteract-
ing PG490-mediated IKKβ-suppressive effects. Secondly,
this in vitro study can not exactly reflect the in vivo situa-
tions, especially the situations in humans. Thirdly, whether
the observations in T cells may happen in other tissue cells
requires additional experiments to examine. Lastly, only a
head-to-head comparison in clinical trials but not in this
study can really tell us whether the observed benefit/risk
of PG27 compared to PG490 does exist. Evidently, more
studies are needed to answer these questions.
Traditional Chinese medicine prescriptions “Fufang” usu-
ally contain several herbs (each called “Danfang”). The trad-
itional Chinese medicinal doctors will modify and adjust
the ingredients and doses of each “Danfang” according to
the need of individual patients. This formulation is based
on the principle of “Junn-Chenn-Zuou-SS”. Therefore, the
commonly accepted working concept of “Junn-Chenn-
Zuou-SS” illustrates the specific coordinated effects from a
combination of different Chinese herbs. In this study, we
provide novel and interesting observations demonstrating
that the “Junn-Chenn-Zuou-SS” theory may also work in a
refined extract PG27 from a single herb TwHf. It is antici-
pated that with the inclusion of more molecular studies on
Chinese herbs, the concept of “Junn-Chenn-Zuou-SS” will
gain more scientific support.
Additional file
Additional file 1: Figure S1. Side-by-side comparisons of PG27 and
PG490 (triptolide) for immunosuppressive potency on CD3/CD28-stimulated
T cells.
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